Inactive Instrument

Titan Pharmaceuticals, Inc. Share Price Nasdaq

Equities

US8883143096

Pharmaceuticals

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2022 6L 4.65Cr Sales 2023 2L 1.54Cr Capitalization 62.15L 52Cr
Net income 2022 -1Cr -83Cr Net income 2023 -50L -42Cr EV / Sales 2022 15.6 x
Net cash position 2022 27.5L 23Cr Net cash position 2023 61.95L 52Cr EV / Sales 2023 0.11 x
P/E ratio 2022
-1.03 x
P/E ratio 2023
-1.11 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 54.53%
More Fundamentals * Assessed data
Dynamic Chart
Members of the board TitleAgeSince
Director/Board Member 53 15/22/15
Chief Executive Officer 42 12/23/12
Director/Board Member - 12/23/12
More insiders
Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW